Effects of Pregnan X Receptor (NR1I2) and CYP2B6 Genetic Polymorphisms on the Induction of Bupropion Hydroxylation by Rifampin

Authors

Jae Yong Chung, Joo-Youn Cho, Hyeong-Seok Lim, Jung-Ryul Kim, Kyung-Sang Yu, Kyoung Soo Lim, Sang-Goo Shin, In-Jin Jang

Department of Pharmacology and Clinical Pharmacology, Yonsei University College of Medicine and Severance Hospital, Seoul, Korea (J.Y.C.); Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital, Seoul, Korea (J.-Y.C., J.-R.K., K.-S.Y., K.S.L., S.-G.S., I.-J.J.); and Department of Clinical Pharmacology & Therapeutics, College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Korea (H.-S.L)
Correspondence:  Dr. Joo-Youn Cho, Ph.D.

Dept. of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-799, Korea. E-mail: joocho@snu.ac.kr, Telephone: 82-2-740-8286, Fax: 82-2-745-7996.

Running Title: PXR & CYP2B6 Variants and Induction of Bupropion Hydroxylation

Text Pages: 26
Tables: 3
Figures: 2
References: 33
Words in the Abstract: 185
Words in the Introduction: 546
Words in the Discussion: 1124

ABBREVIATIONS: AUC, area under the curve; CAR, constitutive androstane receptor; PK, pharmacokinetic; PXR, pregnane X receptor; SNP, single-nucleotide polymorphism
ABSTRACT:

We investigated genetic polymorphisms in the pregnane X receptor (NR1I2) in Korean individuals (n = 83) and the effects of NR1I2 genotypes on rifampin-mediated induction of bupropion hydroxylation. The pharmacokinetics of bupropion and hydroxybupropion were evaluated following an oral dose of bupropion (150 mg) administered before and after rifampin treatment for 7 days in 35 healthy subjects. The AUC ratio of hydroxybupropion to bupropion in CYP2B6*6 carriers was significantly lower than that in CYP2B6*6 non-carriers in both the basal and rifampin-induced states (p = 0.012). Among the CYP2B6*6 carriers (n = 13), the NR1I2 TGT (-25385T+g.7635G+g.8055T) carriers exhibited a significantly lower AUC ratio, representing the CYP2B6 hydroxylation activity, compared with the TGT non-carriers, in the induced state (11.9 vs. 20.3, p= 0.045). The percentage difference in the AUC ratio between the basal and induced states was also significantly different (212% vs. 58.8%, p = 0.006). However, no significant difference was observed among the NR1I2 TGT genotypes for the CYP2B6*6 non-carriers (n = 22). In conclusion, it is suggested the NR1I2 TGT genotype decrease the bupropion hydroxylation induced by treatment with rifampin, particularly in CYP2B6*6 carriers.
Introduction

The Pregnane X receptor (PXR), also known as the steroid and xenobiotic receptor (SXR) or pregnane-activated receptor (PAR), is an orphan nuclear receptor family member and is encoded by the nuclear receptor subfamily 1 (NR1I2) gene (Bertilsson et al., 1998; Blumberg et al., 1998; Lehmann et al., 1998). Following ligand binding, PXR forms a heterodimer with the retinoid X receptor (RXR, NR1B), which then binds to PXR response elements located in the 5'-flanking regions of PXR target genes, resulting in transcriptional activation (Rosenfeld et al., 2003). PXR is a master transcriptional regulator of many important genes involved in xenobiotic metabolism and transport, including genes encoding cytochrome P450s (e.g., CYP3A4, CYP3A5, CYP2B6, CYP2C19, and CYP2C8), transporters (e.g., MDR1 (ABCB1), MRP2 (ABCC2), and OATP2 (SLCO1B1)) (Lamba et al., 2005).

Genetic polymorphisms in NR1I2 may explain the inter-individual variability of PXR activity, which affects the disposition and interaction of various drugs via an induction mechanism. Most previous studies have reported that variant alleles of NR1I2 are associated with decreased rifampin-mediated CYP3A4 induction (Hustert et al., 2001; Koyano et al., 2004; Lim et al., 2005; Wang et al., 2007), but increased transcriptional activation of PXR was observed at SNPs of -25385C>T, -24113G>A, g.7635A>G, or g.8055C>T (Zhang et al., 2001). However, the clinical consequences of these polymorphisms have not been consistently validated, and clinically important variation has not yet been demonstrated by well-controlled clinical pharmacogenetic studies.

CYP2B6 plays a primary role in the metabolism of therapeutic drugs such as cyclophosphamide, bupropion, and efavirenz (Chang et al., 1993; Kirchheiner et al., 2003; Ward et al., 2003). CYP2B6 comprises less than 1% of the total liver microsomal CYP content and is expressed in various extrahepatic tissues, including the brain (Shimada et al., 1994). The CYP2B6 enzyme is highly polymorphic and its genetic polymorphisms have been
discovered relatively in recent (Lang et al., 2001). The common allele \( CYP2B6*6 \) (c.516G>T and c.785A>G) leads to aberrant splicing of pre-mRNA, resulting in reduced expression of functional transcript and protein in human liver (Hofmann et al., 2008). Associations between \( CYP2B6 \) genetic polymorphisms and pharmacokinetics have been reported for bupropion (Kirchheiner et al., 2003), thiotepa (Ekhart et al., 2009), and efavirenz (Rotger et al., 2007).

Bupropion, an atypical antidepressant and smoking cessation aid, was reportedly used as a selective marker of \( CYP2B6 \) activity in previous studies (Faucette et al., 2000). A representative PXR agonist, rifampin, has been shown to induce \( CYP2B6 \) activity as evidenced by significantly increased bupropion hydroxylation after rifampin treatment (Loboz et al., 2006). In that study, subjects with \( CYP2B6*6/*6 \) or \( CYP2B6*1/*6 \) exhibited decreased bupropion clearance relative to subjects with \( CYP2B6*1/*1 \) after rifampin treatment, whereas clearance in the absence of rifampin treatment were similar (Loboz et al., 2006). Based on this preliminary result, rifampin-induced \( CYP2B6 \) activity was suggested to be associated with both the existence of the \( CYP2B6*6 \) allele and certain other factors such as genetic polymorphism of PXR.

Both \( CYP2B6 \) and \( NR1I2 \) polymorphisms may be associated with the clinical pharmacokinetics and/or drug-drug interactions of bupropion; however, there have been no clinical pharmacogenetic studies of \( CYP2B6 \) substrates in the rifampin-induced state in relation to the PXR variants. Therefore, we investigated the genetic polymorphisms in PXR and examined the relationship between these genetic polymorphisms and metabolic induction of bupropion by rifampin administration in humans.
**Materials and Methods**

**Subjects.** Thirty-five healthy, unrelated Korean subjects participated in a clinical pharmacokinetic (PK) study of bupropion. All subjects were healthy, as determined by a medical history, physical examination, vital signs, 12-lead electrocardiogram, drug screening, and routine clinical laboratory tests performed within 3 weeks of the start of the study. Regular heavy drinkers, smokers of more than 10 cigarettes per day, and those with a body weight differing by more than 20% from their ideal weight were excluded.

To survey *NR1I2* genetic polymorphisms in the Korean population, a total of 83 individual samples from subjects who had donated blood, including the patients in this PK study, were genotyped. *CYP2B6* genotypes were divided into *CYP2B6*<sup>*</sup>6 carrier and non-carrier groups using methods described previously (Jinno et al., 2003; Hofmann et al., 2008). This study was approved by the Institutional Review Board of Seoul National University Hospital, Seoul, Korea. All procedures were performed in accordance with the recommendations of the Declaration of Helsinki on biomedical research involving human subjects, and with the International Conference on the Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use–Good Clinical Practice guidelines. Written informed consent for participation in the study and genotyping was obtained from all subjects before enrollment.

**Study Design.** The subjects were admitted to the clinical research ward of the Clinical Trials Center on the night before bupropion administration. After an overnight fast, subjects were given a single dose of 150 mg bupropion (Wellbutrin<sup>®</sup> SR tablet; GlaxoSmithKline Korea, Seoul, Korea) with 240 ml of water at 9 am on day 1. Subjects fasted for 4 hours after drug administration, other than drinking water 2 hours after dosing. Venous blood samples for PK analysis (8 ml) were collected using an intravenous catheter before dosing and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 9, 12, 24, 30, and 36 hours after dosing. Alcohol, soft drinks, smoking,
drugs, and caffeine-containing beverages were prohibited during the study. After 7 days of washout, subjects were given 600 mg of rifampin (Rifodex® tablet, ChongKunDang Pharmaceutical Corp., Seoul, Korea) every morning, on an outpatient basis, on days 8–14. On day 15, after overnight fasting, subjects were given 150 mg of bupropion in the same manner as described for day 1.

**Genotyping**

**NR1I2.** Genomic DNA was extracted from peripheral whole blood using a QIAamp DNA Blood Mini kit (QIAGEN GmbH, Germany). Genotyping was done using TaqMan allelic discrimination assays on an AB 7500 Real time PCR System (Applied Biosystems, Foster City, CA, USA). Ten microliters of PCR reaction mixture were prepared with 5 μl of 2× TaqMan Genotyping Master mix, 0.5 μl of 20× Drug Metabolism Genotyping Assay Mix, 3.5 μl of DNase-free water, and 1 μl of genomic DNA. Genotyping for NR1I2 -25385C>T (rs3814055, Assay ID: C__27504984_30), NR1I2 -24113G>A (rs2276706, Assay ID: C__15882316_10), NR1I2 g.7635A>G (rs6785049, Assay ID: C__29280426_10), and NR1I2 g.8055C>T (rs2276707, Assay ID: C__15882324_10) Detection of SNPs was performed with validated TaqMan genotyping assays purchased from Applied Biosystems. The PCR reactions were as follows: initial denaturation at 95°C for 10 min, followed by 50 cycles of denaturation at 92°C for 15 s and annealing/extension at 60°C for 1 min. The allelic discrimination results were determined after amplification by performing an end-point read. AB Sequence Detection System (SDS) 7500 software ver 1.4 (Applied Biosystems) was used for the analysis.

**DNA direct sequencing.** To identify NR1I2 -24020[GAGAAG]>(-) (rs3842689) sequencing was applied. The PCR method was used to amplify one NR1I2 fragment with UCSC In-Silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr?command=start). The final volume of the PCR was 10 μl, consisting of 10 ng of DNA, 0.5 μM of each primer pair,
0.25 mM dNTPs, 3 mM MgCl$_2$, 1 μl 1× reaction buffer, and 0.25 U Taq DNA polymerase (Intron Biotechnology, Seongnam-si, Gyeonggi-do, Korea). The PCR products were purified and sequenced using a BigDye Terminator Cycle Sequencing kit and an ABI 3730xl automated sequencer (Applied Biosystems). The sequencing primers were the same as those used for the PCR amplification. Mutation analyses were performed using Phred, Phrap, Consed, PolypHred 5.04 software (http://droog.mbt.washington.edu/PolypHred.html).

**CYP2B6.** Genomic DNA was prepared from peripheral blood samples using the nucleic acid isolation device QuickGene-Mini80 (Fujifilm, Tokyo, Japan). To determine the presence of CYP2B6*4 (c.785A>G only) and CYP2B6*6 (c.516G>T and c.785A>G), DNA proximal to two polymorphic sites, c.785A>G (rs2279343) and c.516G>T (rs3745274), was amplified by PCR, followed by SNaPShot analysis according to the manufacturer’s instructions (ABI PRISM SNaPShot Multiplex kit). The sequences of forward and reverse primers and probes were 5′-CTTTCTTGCAGCTGTTTG-3′, 5′-CCTCTGTCTTTCATTCTGTC-3′, and 5′-GGTAGGTGTCGATGAGGTCC-3′ for c.785A>G, and 5′-CGTGACGTGCTGGTACA-3′, 5′-CTCCATGTCCCTGATTCTT-3′, and 5′-AGATGATGTTGGCGGTAAATGGA-3′ for c.516G>T, respectively. The validity of the method was confirmed by sequencing.

**Drug Concentration Analysis.** The plasma concentrations of bupropion and hydroxybupropion were determined by high-performance liquid chromatography (HPLC) with ultraviolet detection using a modification of a previously described method (Jennison et al., 1995). Standards of bupropion and hydroxybupropion were purchased from BD Gentest (Woburn, MA, USA) and trazodone as an internal standard was obtained from Sigma-Aldrich (St. Louis, MO, USA). One milliliter of plasma was extracted with 10 ml of n-heptane:isoamyl alcohol (1000:15, v/v) including 25 μg of trazodone as an internal standard after the addition of 150 μl of 0.1 M hydrochloride. The organic phase was evaporated,
reconstituted with 100 μl of the mobile phase, and injected into an HPLC system (Gilson, Villiers-le-Bil, France). A mobile phase of 50 mM KH₂PO₄:acetonitrile (810:190, v/v, pH 2.5) was used at a flow rate of 1.0 ml/min through a Capcell Pak C₁₈ column (150-× 4.6-mm i.d., 5.0-mm particle size, Shiseido, Tokyo, Japan). The ultraviolet detector was set to monitor 214 nm. The lower limit of quantification (LLOQ) for bupropion and hydroxybupropion was 2 ng/ml and 10 ng/ml, respectively, and the calibration curves for bupropion and hydroxybupropion were linear from LLOQ to 1000 ng/ml (correlation coefficient >0.997). The accuracy was 91.9-106.1% for bupropion and 100.6-111.5% for hydroxybupropion, while the inter-batch coefficients of variation were <7.7 and <9.2% for bupropion and hydroxybupropion, respectively.

**Pharmacokinetics and Statistical Analysis.** PK parameters were calculated using the actual sampling times. Maximum plasma drug concentrations (C_max) were determined from the observed values. Plasma concentrations for the terminal phase were fitted to a log-linear line using the least-squares method to obtain the terminal half-life (t₁/₂). Areas under the time-concentration curve for bupropion (AUC_bup) and hydroxybupropion (AUC_hyd) were calculated using a combination of the trapezoidal rule from 0 to 36 hours. AUC_hyd was divided by AUC_bup for each period, representing the activity of metabolite formation of bupropion to hydroxybupropion (formation clearance divided by metabolite clearance). Percentage differences in the PK parameters between the basal and rifampin-induced states were used to assess the induction effect of rifampin treatment, and were calculated as 100 × (induced – basal) / basal. WinNonlin version 5.2 (Pharsight Co., St. Louis, MO, USA) was used for the PK analysis.

Considering the small and uneven number of subjects, comparisons of parameters between the two groups was conducted nonparametrically using the Wilcoxon rank sum test. Comparisons of parameters between the metabolic induced state and the basal state for each
subject were conducted using a paired t-test. Multiple linear regression analysis was applied to evaluate the significance of effects due to genotype, gender, and body weight and their contributions to the total observed variability. \( p \) values < 0.05 were considered statistically significant. Linkage disequilibrium and haplotype assembly analysis were performed using the Haploview 4.1 program (Broad Institute of Harvard and MIT, Cambridge, MA, USA), based on a standard expectation maximization algorithm, to reconstruct individual haplotypes from the population genotype data.
Results

Genetic Polymorphisms of *NR1I2* in the Korean Population. The frequencies of the *NR1I2* alleles -25385C, -24113G, -24020[GAGAAG], g.7635A, and g.8055C in the 83 samples were 0.681, 0.681, 0.681, 0.518, and 0.590, respectively. The distribution of the genotypes was consistent with Hardy-Weinberg equilibrium (*p* > 0.05, chi-square test). *NR1I2* -25385C>T, -24113G>A, and -24020[GAGAAG]>(-) displayed 100% linkage (*r^2* = 1.0), and a significant linkage (*r^2* = 0.746) was found between g.7635A>G and g.8055C>T. Single nucleotide polymorphisms (SNPs) in positions -25385, g.7635, and g.8055 resulted in six haplotypes: CAC, CGT, TGT, TAC, CGC, and TGC, with population frequencies of 0.428, 0.211, 0.199, 0.090, 0.042, and 0.030, respectively. The CAC haplotype was the most common and was regarded as the wild-type allele, and the CGT and TGT haplotypes were the primary variant alleles, based on their allele frequencies. Considering that the -25385C>T SNP has previously been reported to exhibit altered transcriptional activity (Zhang et al., 2001; Wang et al., 2009), the subjects were divided into TGT carrier (n = 13) and non-carrier (n = 22) groups, based on the existence of the *NR1I2* TGT haplotype, as well as the -25385C>T SNP.

Results of the Clinical Study. The demographic characteristics of the subjects and the distributions of the *CYP2B6* genotypes were not significantly different among the *NR1I2* haplotypes (Table 1). After rifampin treatment, AUC_bup markedly decreased and AUC_hyd/AUC_bup, which represents the metabolic activity of bupropion into hydroxybupropion, significantly increased (*p* < 0.001, paired t-test). The percentage differences were significantly greater in the *NR1I2* TGT non-carriers (228%) than in the TGT carriers (169%) (*p* = 0.018). AUC_hyd in the TGT non-carriers did not differ between the basal and induced states (0.43%, *p* = 0.464), whereas in the TGT carriers it was significantly decreased in the induced state (-24.8%, *p* = 0.0002). As a result, there were significant
differences among the NR1I2 genotypes in terms of the percentage difference in AUC_hyd between the basal and induced states ($p < 0.001$). These findings were consistent with the results grouped by the -25385TT genotypes (Table 2). However, there was no significant difference in AUC_bup, AUC_hyd, or their ratios between the NR1I2 TGT carriers and non-carriers, or between the -25385CC and CT groups, in either the basal or induced metabolic states (Table 2).

The effects of the CYP2B6 and NR1I2 genotypes were considered together and are shown by subgroup in Table 3. The CYP2B6*6 carriers had significantly lower AUC_hyd and AUC_hyd/AUC_bup compared to the CYP2B6*6 non-carriers in both the basal and induced states. The percentage differences in AUC_hyd after rifampin treatment were significantly different among the NR1I2 genotypes, regardless of the CYP2B6 genotype.

There were no significant differences found in AUC_hyd/AUC_bup among the NR1I2 TGT genotypes for the CYP2B6*6 non-carriers. In contrast, for the CYP2B6*6 carriers, the NR1I2 TGT carriers had a significantly lower AUC_hyd/AUC_bup than the TGT non-carriers in the induced state (11.9 versus 20.3, $p = 0.045$), and the percentage difference after rifampin induction was significantly different (212% versus 58.8%, $p = 0.006$) (Table 3). Individual plots of AUC_hyd/AUC_bup by CYP2B6 and NR1I2 genotypes for each period indicate much lower increases for the NR1I2 TGT + CYP2B6*6 carriers (Fig. 1).

The concentration-time profiles for bupropion were similar regardless of genotype for both metabolic states. However, the profiles for hydroxybupropion were different for the CYP2B6*6 + NR1I2 TGT carriers than for the other groups, with lower values in the basal state and much lower values in the induced state (Fig. 2). The maximum concentrations ($C_{max}$) of bupropion and hydroxybupropion in the basal and induced states were not significantly different between the NR1I2 TGT carriers and non-carriers (data not shown).
the basal state, the hydroxybupropion $C_{\text{max}}$ for the TGT carriers (499.2 ± 190.9 ng/ml) was slightly higher than that for the TGT non-carriers (382.9 ± 134.3 ng/ml, $p = 0.088$).

Multiple linear regression analysis of the % difference of $\text{AUC}_{\text{hyd}}/\text{AUC}_{\text{bup}}$, including the demographic and genetic factors, showed that only the $NR1I2$ TGT haplotype had a significant effect ($p = 0.0049$) and explained 22.2% ($r^2 = 0.222$) of the total variability. The $r^2$ value increased to 0.356 when the model included body weight, the $CYP2B6$ genotype, or gender variables (partial $r^2 = 0.061, 0.048$, and 0.025, respectively).
Discussion

We investigated genetic polymorphisms in *NR1I2* in the Korean population. Allele frequencies of -25385C>T and -24020 6-bp del were similar to other ethnic groups, and that of g.7685A>G and g.8055C>T were slightly higher than Caucasian and African-American populations. Strong linkage among the -25385, -24113, and -24020 SNPs was identified, as previously reported (Zhang et al., 2001; Uno et al., 2003; Lamba et al., 2005; Wang et al., 2007).

We found that the percentage differences in AUC_hyd and AUC_hyd/AUC_bup after rifampin treatment were significantly different between the *NR1I2* TGT carriers and non-carriers. These differences were highly significant in the *CYP2B6*<sup>6</sup> carriers, with the lowest value observed in the *NR1I2* TGT carrier group (58%, the percentage increase of the AUC_hyd/AUC_bup). However, significant differences were not observed among the *CYP2B6*<sup>6</sup> non-carriers. These findings support the hypothesis that the increased metabolism of bupropion with rifampin treatment is affected by both *NR1I2* and *CYP2B6* genetic polymorphisms. Specifically, it can be postulated that reduced metabolic capacity is more pronounced in individuals with both the *CYP2B6*<sup>6</sup> and reduced function PXR alleles.

Since Zhang et al. (Zhang et al., 2001) reported that several variant *NR1I2* genotypes exhibited increased induction activity after rifampin treatment, various studies have suggested certain effects of PXR variants, despite inconsistent results. Higher mRNA levels of intestinal CYP3A4 were associated with g.7635G and g.8055T, and greater induction of CYP3A activity was found in -25385TT subjects than in -25385CC subjects, as measured by an erythromycin breath test (Zhang et al., 2001). In addition, a recent report showed that the *NR1I2* haplotype, including TGT, was associated with weaker basal activity but greater inducible transcriptional activity of CYP3A4, based on a PK study of nifedipine (Wang et al., 2009). However, these studies were examined using CYP3A4 substrates, a very small sample
size (n = 3), and limited in vivo PK information regarding the substrate drugs, and also their associated mechanism has not been experimentally demonstrated. Consistent with our findings, most studies have suggested that the same PXR genetic variants exhibited reduced PXR transcriptional activity. A 6-bp deletion in intron 1a (-24020), which was linked completely to -25385C>T and -24113G>A SNPs in our study, has been reported to be associated with a total loss of transcriptional activity when expressed in the HepG2 cell line (Uno et al., 2003). This observation is consistent with the results for one of our subjects with -25385TT, who had the lowest percentage increase (34.2%) in AUC_hyd/AUC_bup after rifampin induction. In patients with primary sclerosing cholangitis, which is caused by abnormal bile acid detoxification, the rs6785049 (g.7635A>G) GG group exhibited a reduced survival rate associated with decreased transcription activity of PXR (Karlsen et al., 2006). Another example of clinically decreased PXR transactivation in a PXR variant was shown in breast cancer patients who took doxorubicin. PXR*1B haplotypes, which consisted of g.2654T>C and IVS6-17C>T polymorphisms, were found to be associated with significantly decreased hepatic mRNA expression of PXR and its downstream target genes, CYP3A4 and ABCB1. The PXR*1B haplotype was also significantly associated with reduced clearance of doxorubicin (Sandanaraj et al., 2008).

In the basal state, the mean value of AUC_hyd/AUC_bup was somewhat higher in the NR1I2 TGT carriers than non-carriers (more prominently in the CYP2B6*6 non-carriers, p = 0.066). The reason for this is unknown, but this phenomenon was also reported in an in vitro study of PXR.2 expression. PXR.2 is an alternatively spliced form of PXR that lacks 111 nucleotides encoding 37 amino acids in the ligand-binding domain. Basal CYP2B6 expression levels are increased in untreated PXR.2 cells: however, CYP2B6 induction activity decreased after treatment with rifampin (Lin et al., 2009). Other effects may be linked to the NR1I2 TGT haplotype and basal metabolic activity of CYP2B6. For example,
impaired transactivation of PXR may initiate other induction pathways leading to compensation or overcompensation, depending on the circumstances.

Our results suggest that the CYP2B6*6 allele is associated with reduced metabolic biotransformation regardless of the NR1I2 genotype. In vitro studies of the CYP2B6 substrates, bupropion and efavirenz, have demonstrated that the *6 allele expresses up to 4-fold less protein with lower activity than the wild-type allele (Desta et al., 2007). The molecular mechanism associated with the CYP2B6*6 allele involves aberrant splicing, leading to lower functional mRNA and protein levels as well as reduced activity (Hofmann et al., 2008). Bupropion is associated with several safety problems including seizures (Ross and Williams, 2005), and failure to achieve smoking cessation in certain groups, which may be due to differences in metabolic induction. Therefore, the knowledge of a patient’s genotype may help determine the optimal regimen for bupropion, especially when considering drug interactions. Moreover, the expression of the CYP2B6 protein and mRNA is region-specific (Gervot et al., 1999). Expression has been observed in neurons and astrocytes in the human brain (Miksys et al., 2003), the target site of bupropion, suggesting that the NR1I2 and CYP2B6 genotypes may be more closely associated with clinical effects than would be suggested by the apparent PK parameters obtained from plasma data. In addition, transporter activity at the blood-brain barrier must be considered in this context. Thus, the influence of NR1I2 polymorphisms on the clinical efficacy and adverse effects of bupropion should be examined in the future a large-scale controlled clinical study.

The primary limitation of this study was the small number of volunteers in the variant type groups. However, at a minimum it may be confidently inferred that the effect of the NR1I2 genotype is small for CYP2B6*6 non-carriers (n = 22). In addition, we were not able to examine all of the known functional polymorphisms of PXR; instead, considering the small number of subjects, we focused on five sites that are frequently found in Asian individuals. A
potential role for other nuclear receptors, such as the constitutive androstane receptor (CAR), farnesoid X receptor, and glucocorticoid receptor, as well as metabolizing enzymes and drug transporters in bupropion disposition and rifampin-mediated induction, may be postulated. CAR is well known to be related to CYP2B activation (Honkakoski and Negishi, 1998). A different mechanism of induction is evident in metamizole, which does not act as a direct ligand for PXR or CAR, but selectively increases human hepatic CYP2B6 and CYP3A4 expression and activity (Saussele et al., 2007). Further investigation of the in vivo effects of CAR and other factors together with PXR and CYP2B6 in the induction of bupropion hydroxylation is therefore needed.

In conclusion, our study suggests that the NR1I2 TGT or -25385T haplotype may decrease the induced metabolism of bupropion after rifampin administration in CYP2B6*6 carriers, whereas this effect was not significant in CYP2B6*6 non-carriers. Controlled pharmacogenetic clinical studies and large-scale pharmacodynamic genetic polymorphism studies in patients are both needed to clarify the role of the NR1I2 polymorphism in the efficacy, safety, and drug interactions of CYP2B6 substrate drugs.
DMD 035246

Acknowledgements

We thank Ka-Heon Song for her excellent technical assistance with drug concentration analysis.

Conflict of interest statement:

None of the authors have any conflict of interest regarding this study.
References


Lamba J, Lamba V and Schuetz E (2005) Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6:369-383.


Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of


Footnotes

This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health & Welfare, Republic of Korea [A030001].
Legends for Figures

FIG. 1. Individual subject profiles showing the ratios of the hydroxybupropion AUCs to the bupropion AUCs (AUC_hydro/AUC_bup) for the basal and rifampin-induced states in the NR1I2 and CYP2B6 genotype groups (n = 35).

FIG. 2. Mean plasma concentration-time profiles of bupropion and hydroxybupropion after oral administration of 150 mg bupropion in the NR1I2 and CYP2B6 genotype groups (A: CYP2B6*6 non-carrier + NR1I2 TGT non-carrier, B: CYP2B6*6 non-carrier + NR1I2 TGT carrier, C: CYP2B6*6 carrier + NR1I2 TGT non-carrier, D: CYP2B6*6 carrier + NR1I2 TGT carrier). The dashed and solid lines indicate basal and rifampin-induced states, respectively. BUP indicates bupropion.
### Tables

**TABLE 1. Demographic data and CYP2B6 genotypes in the subjects of the NR1I2 TGT haplotype groups**

<table>
<thead>
<tr>
<th>Genotype</th>
<th>TGT non-carrier</th>
<th>TGT carrier</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n)</td>
<td>(22)</td>
<td>(13)</td>
<td></td>
</tr>
<tr>
<td>Number of</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjects (n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>16</td>
<td>5</td>
<td>0.0751†</td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>22.7±1.6</td>
<td>23.2±2.3</td>
<td>0.9715††</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>65.0±10.1</td>
<td>59.5±11.5</td>
<td>0.0941††</td>
</tr>
<tr>
<td>CYP2B6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>*1/*1 (19)+*1/*4 (3)</td>
<td>13</td>
<td>9</td>
<td>0.6638†</td>
</tr>
<tr>
<td>*1/*6(11)+*6/*6(2)</td>
<td>9</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

† Fisher’s exact test
†† Wilcoxon rank sum test between the two groups;
TABLE 2. Effects of NR1I2 genotypes on the rifampin-mediated metabolic induction of bupropion hydroxylation

<table>
<thead>
<tr>
<th>NR1I2 Genotype (Number of subjects)</th>
<th>TGT non-carrier (22)</th>
<th>TGT carrier (13)</th>
<th>P†</th>
<th>-25385CC (17)</th>
<th>-25385CT (17)</th>
<th>-25385TT (1)</th>
<th>PT†</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC_bup (ng*hr/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal</td>
<td>1.274±324</td>
<td>1.194±315</td>
<td>0.585</td>
<td>1.260±350</td>
<td>1.247±294</td>
<td>929</td>
<td>0.5525</td>
</tr>
<tr>
<td>Induced</td>
<td>435±196</td>
<td>406±176</td>
<td>0.785</td>
<td>418.2±212.5</td>
<td>432.6±168.1</td>
<td>370</td>
<td>0.8505</td>
</tr>
<tr>
<td>% Difference</td>
<td>-66.7±10.4*</td>
<td>-65.1±15.8*</td>
<td>0.960</td>
<td>-67.8±11.2*</td>
<td>-64.8±14.1*</td>
<td>-60.2</td>
<td>0.607</td>
</tr>
<tr>
<td>AUC_hyd (ng*h/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal</td>
<td>9,343±3,118</td>
<td>11,558±4,568</td>
<td>0.204</td>
<td>9,290±3,276</td>
<td>10,695±4,112</td>
<td>16,053</td>
<td>0.231</td>
</tr>
<tr>
<td>Induced</td>
<td>9,003±2,435</td>
<td>8,541±3,304</td>
<td>0.489</td>
<td>8,840±2,413</td>
<td>8,837±3,202</td>
<td>8577</td>
<td>0.941</td>
</tr>
<tr>
<td>% Difference</td>
<td>0.43±23.3</td>
<td>-24.8±11.8*</td>
<td>&lt;0.001</td>
<td>-0.78±20.2</td>
<td>-14.8±23.2*</td>
<td>-46.6</td>
<td>0.017</td>
</tr>
<tr>
<td>AUC_hyd/AUC_bup</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal</td>
<td>7.7±3.1</td>
<td>10.3±4.6</td>
<td>0.088</td>
<td>7.8±3.4</td>
<td>9.0±3.9</td>
<td>17.3</td>
<td>0.195</td>
</tr>
<tr>
<td>Induced</td>
<td>26.0±19.2</td>
<td>27.3±17.0</td>
<td>0.759</td>
<td>27.9±21.5</td>
<td>25.3±15.3</td>
<td>23.2</td>
<td>0.978</td>
</tr>
<tr>
<td>% Difference</td>
<td>228±95*</td>
<td>169±176*</td>
<td>0.018</td>
<td>232±98.3*</td>
<td>182±153*</td>
<td>34.2</td>
<td>0.035</td>
</tr>
</tbody>
</table>

AUC_bup, area under the time-concentration curve of bupropion; AUC_hyd, AUC of hydroxybupropion; % Difference, percentage difference between basal and induced state, calculated as 100*(Induced – Basal)/Basal; †Wilcoxon rank-sum test for the NR1I2 groups; ††Kruskal-Wallis test for -25385C>T groups; P< 0.05 indicated as bold
#P<0.01, paired t-test between the basal and induced states
TABLE 3. Effects of the CYP2B6 genotype and NR1I2 genotypes on rifampin-mediated metabolic induction of bupropion hydroxylation

<table>
<thead>
<tr>
<th>CYP2B6 Genotype (n)</th>
<th>CYP2B6*6 non-carrier (22)</th>
<th>CYP2B6*6 carrier (13)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TGT non-carrier (13)</td>
<td>TGT carrier (9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NR1I2 Group (n)</th>
<th>Basal</th>
<th>Induced</th>
<th>% Difference</th>
<th>Basal</th>
<th>Induced</th>
<th>% Difference</th>
<th>Basal</th>
<th>Induced</th>
<th>% Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC_bup (ng*hr/ml)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1,307±318</td>
<td>437±188</td>
<td>67.2±10.8</td>
<td>1,046±3,112</td>
<td>9,849±1,923</td>
<td>0.22±28.0</td>
<td>-9.39±25.1</td>
<td>8.6±3.5</td>
<td>30.0±23.5</td>
</tr>
<tr>
<td></td>
<td>1,257±312</td>
<td>399±180</td>
<td>68.7±11.3</td>
<td>11,419±3,609</td>
<td>9,811±2,378</td>
<td>-23.3±10.5</td>
<td>-3.9±25.1</td>
<td>9.7±3.8</td>
<td>31.7±20.3</td>
</tr>
<tr>
<td></td>
<td>1,227±347</td>
<td>430.6±216.7</td>
<td>65.8±10.4</td>
<td>7,723±2,449</td>
<td>7,782±2,680</td>
<td>0.76±15.8</td>
<td>6.5±2.0</td>
<td>20.3±8.9</td>
<td>212±78</td>
</tr>
<tr>
<td></td>
<td>1,209±376</td>
<td>545.2±132.3</td>
<td>52.3±16.8</td>
<td>8,776±5,073</td>
<td>5,808±2,117</td>
<td>-28.1±15.6</td>
<td>8.0±6.2</td>
<td>11.9±7.7</td>
<td>58.8±41.9</td>
</tr>
<tr>
<td></td>
<td>0.333</td>
<td>0.243</td>
<td>0.512</td>
<td>0.324</td>
<td>0.845</td>
<td>0.021</td>
<td>0.066</td>
<td>0.333</td>
<td>0.262</td>
</tr>
<tr>
<td></td>
<td>0.877</td>
<td>0.165</td>
<td>0.199</td>
<td>0.940</td>
<td>0.199</td>
<td>0.011</td>
<td>0.758</td>
<td>0.045</td>
<td>0.468</td>
</tr>
<tr>
<td></td>
<td>0.539</td>
<td>0.306</td>
<td>0.649</td>
<td>0.004</td>
<td>0.013</td>
<td>0.468</td>
<td>0.287</td>
<td>0.012</td>
<td>0.012</td>
</tr>
</tbody>
</table>

| AUC_hyd (ng*h/ml) |       |         |              |       |         |              |       |         |              |
|                  | 10,465±3,112 | 9,756±3,050 | 0.22±28.0 | 11,419±3,609 | 9,811±2,378 | -23.3±10.5 | -3.9±25.1 | 8.6±3.5 | 30.0±23.5 | 228±107 |
|                  | 12,796±4,007 | 12,796±4,007 | -23.3±10.5 | 12,796±4,007 | 12,796±4,007 | 0.76±15.8 | 6.5±2.0 | 20.3±8.9 | 212±78 |
|                  | 7,723±2,449 | 7,782±2,680 | -28.1±15.6 | 7,776±5,073 | 5,808±2,117 | 58.8±41.9 | 8.0±6.2 | 11.9±7.7 | 58.8±41.9 |
|                  | 8,047±3,269 | 8,047±3,269 | 8.0±6.2 | 8,047±3,269 | 8,047±3,269 | 58.8±41.9 | 8.0±6.2 | 11.9±7.7 | 58.8±41.9 |
|                  | 0.324 | 0.845 | 0.021 | 0.324 | 0.845 | 0.021 | 0.324 | 0.845 | 0.021 | 0.324 |
|                  | 0.324 | 0.845 | 0.021 | 0.324 | 0.845 | 0.021 | 0.324 | 0.845 | 0.021 | 0.324 |
|                  | 0.324 | 0.845 | 0.021 | 0.324 | 0.845 | 0.021 | 0.324 | 0.845 | 0.021 | 0.324 |

†Wilcoxon rank-sum test for the NR1I2 groups within each CYP2B6 genotype group; ††Wilcoxon rank-sum test for the CYP2B6 groups. See the footnote to Table 2; P<0.05 is indicated in bold.
FIG. 1

**CYP2B6*6 non-carrier**

<table>
<thead>
<tr>
<th>TGT non-carrier</th>
<th>TGT carrier</th>
</tr>
</thead>
</table>

**CYP2B6*6 carrier**

<table>
<thead>
<tr>
<th>TGT non-carrier</th>
<th>TGT carrier</th>
</tr>
</thead>
</table>

AUC_{hyd} / AUC_{bup} vs. Metabolic State (1=Basal, 2=Induced)
FIG. 2

(A) Basal hydroxyBUP
Induced hydroxyBUP
Basal BUP
Induced BUP

(B) 

(C) 

(D) 

Plasma Concentration (ng/ml)

Time (hr)